Phase 3 N=1,008 Reevaluation Of Systemic Early Neuromuscular Blockade
Acute Respiratory Distress Syndrome
Primary: Hospital Mortality to Day 90 — 288; 289; 213; 216 Participants — p=0.93
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=572 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Breast Cancer
Primary: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort — 11.0; 5.7 Months — p=0.00065
Phase 3 N=57 Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Choriocarcinoma · FIGO Stage I Gestational Trophoblastic Tumor · FIGO Stage II Gestational Trophoblastic Tumor
Primary: Percentage of Participants With Complete Response — 78.6; 88.5 percentage of participants
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 3 N=613 A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Chronic Kidney Disease
Primary: Kaplan-Meier Estimate of Secondary AVF Patency — NA; NA Days — p=0.932
Phase 3 N=8 ACTH for Fatigue in Multiple Sclerosis Patients
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
Phase 3 N=270 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
Choroidal Neovascularization · Macular Edema · Glaucoma, Neovascular
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 21; 1; 0 Participants
Phase 3 N=679 Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) at Day 8 as Assessed by Investigator — 7.8; 8.1; 7.9; 8.0 Scores on a scale — p=0.95
Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Phase 3 N=345 Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)
Seasonal Allergic Rhinitis
Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) (Average of Morning [AM]/Evening [PM] Score) Averaged Over Days 1 to 15 (Participant-Evaluated) — 7.6; 7.3…
Phase 3 N=597 Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Primary: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 — -0.38; -0.30 percentage of HbA1c
Phase 3 N=1,297 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Prostate Cancer Metastatic
Primary: Overall Survival — 34.4; 33.2; 34.3 Months — p=0.4742
Phase 3 N=80 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Carcinoma, Non-Small-Cell Lung
Primary: Progression-free Survival — 1.6; 3.0 months
Phase 3 N=8 A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
Hereditary Angioedema (HAE)
Primary: Time to Onset of Symptom Relief (TOSR) — 1.75 Hours
Phase 3 N=120 Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
Skin Diseases, Infectious · Skin Diseases, Bacterial
Primary: Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs — 13; 3 Participants